148 related articles for article (PubMed ID: 15801822)
1. 9-hydroxyazafluorenes and their use in thrombin inhibitors.
Stauffer KJ; Williams PD; Selnick HG; Nantermet PG; Newton CL; Homnick CF; Zrada MM; Lewis SD; Lucas BJ; Krueger JA; Pietrak BL; Lyle EA; Singh R; Miller-Stein C; White RB; Wong B; Wallace AA; Sitko GR; Cook JJ; Holahan MA; Stranieri-Michener M; Leonard YM; Lynch JJ; McMasters DR; Yan Y
J Med Chem; 2005 Apr; 48(7):2282-93. PubMed ID: 15801822
[TBL] [Abstract][Full Text] [Related]
2. Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.
Lee K; Park CW; Jung WH; Park HD; Lee SH; Chung KH; Park SK; Kwon OH; Kang M; Park DH; Lee SK; Kim EE; Yoon SK; Kim A
J Med Chem; 2003 Aug; 46(17):3612-22. PubMed ID: 12904065
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability.
Staas DD; Savage KL; Sherman VL; Shimp HL; Lyle TA; Tran LO; Wiscount CM; McMasters DR; Sanderson PE; Williams PD; Lucas BJ; Krueger JA; Lewis SD; White RB; Yu S; Wong BK; Kochansky CJ; Anari MR; Yan Y; Vacca JP
Bioorg Med Chem; 2006 Oct; 14(20):6900-16. PubMed ID: 16870455
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support.
Brady SF; Stauffer KJ; Lumma WC; Smith GM; Ramjit HG; Lewis SD; Lucas BJ; Gardell SJ; Lyle EA; Appleby SD; Cook JJ; Holahan MA; Stranieri MT; Lynch JJ; Lin JH; Chen IW; Vastag K; Naylor-Olsen AM; Vacca JP
J Med Chem; 1998 Jan; 41(3):401-6. PubMed ID: 9464370
[TBL] [Abstract][Full Text] [Related]
5. Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.
Tucker TJ; Lumma WC; Lewis SD; Gardell SJ; Lucas BJ; Baskin EP; Woltmann R; Lynch JJ; Lyle EA; Appleby SD; Chen IW; Dancheck KB; Vacca JP
J Med Chem; 1997 May; 40(11):1565-9. PubMed ID: 9171866
[TBL] [Abstract][Full Text] [Related]
6. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.
Isaacs RC; Solinsky MG; Cutrona KJ; Newton CL; Naylor-Olsen AM; McMasters DR; Krueger JA; Lewis SD; Lucas BJ; Kuo LC; Yan Y; Lynch JJ; Lyle EA
Bioorg Med Chem Lett; 2008 Mar; 18(6):2062-6. PubMed ID: 18291642
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
9. Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.
Burgey CS; Robinson KA; Lyle TA; Sanderson PE; Lewis SD; Lucas BJ; Krueger JA; Singh R; Miller-Stein C; White RB; Wong B; Lyle EA; Williams PD; Coburn CA; Dorsey BD; Barrow JC; Stranieri MT; Holahan MA; Sitko GR; Cook JJ; McMasters DR; McDonough CM; Sanders WM; Wallace AA; Clayton FC; Bohn D; Leonard YM; Detwiler TJ; Lynch JJ; Yan Y; Chen Z; Kuo L; Gardell SJ; Shafer JA; Vacca JP
J Med Chem; 2003 Feb; 46(4):461-73. PubMed ID: 12570369
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.
Bunnage ME; Blagg J; Steele J; Owen DR; Allerton C; McElroy AB; Miller D; Ringer T; Butcher K; Beaumont K; Evans K; Gray AJ; Holland SJ; Feeder N; Moore RS; Brown DG
J Med Chem; 2007 Nov; 50(24):6095-103. PubMed ID: 17990866
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.
Tucker TJ; Brady SF; Lumma WC; Lewis SD; Gardell SJ; Naylor-Olsen AM; Yan Y; Sisko JT; Stauffer KJ; Lucas BJ; Lynch JJ; Cook JJ; Stranieri MT; Holahan MA; Lyle EA; Baskin EP; Chen IW; Dancheck KB; Krueger JA; Cooper CM; Vacca JP
J Med Chem; 1998 Aug; 41(17):3210-9. PubMed ID: 9703466
[TBL] [Abstract][Full Text] [Related]
12. P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position.
Isaacs RC; Newton CL; Cutrona KJ; Mercer SP; Dorsey BD; McDonough CM; Cook JJ; Krueger JA; Lewis SD; Lucas BJ; Lyle EA; Lynch JJ; Miller-Stein C; Michener MT; Wallace AA; White RB; Wong BK
Bioorg Med Chem Lett; 2011 Mar; 21(5):1532-5. PubMed ID: 21295466
[TBL] [Abstract][Full Text] [Related]
13. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
Crane SN; Black WC; Palmer JT; Davis DE; Setti E; Robichaud J; Paquet J; Oballa RM; Bayly CI; McKay DJ; Somoza JR; Chauret N; Seto C; Scheigetz J; Wesolowski G; Massé F; Desmarais S; Ouellet M
J Med Chem; 2006 Feb; 49(3):1066-79. PubMed ID: 16451072
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
Vendeville S; Nilsson M; de Kock H; Lin TI; Antonov D; Classon B; Ayesa S; Ivanov V; Johansson PO; Kahnberg P; Eneroth A; Wikstrom K; Vrang L; Edlund M; Lindström S; Van de Vreken W; McGowan D; Tahri A; Hu L; Lenz O; Delouvroy F; Van Dooren M; Kindermans N; Surleraux D; Wigerinck P; Rosenquist A; Samuelsson B; Simmen K; Raboisson P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6189-93. PubMed ID: 18954982
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position.
Feng DM; Gardell SJ; Lewis SD; Bock MG; Chen Z; Freidinger RM; Naylor-Olsen AM; Ramjit HG; Woltmann R; Baskin EP; Lynch JJ; Lucas R; Shafer JA; Dancheck KB; Chen IW; Mao SS; Krueger JA; Hare TR; Mulichak AM; Vacca JP
J Med Chem; 1997 Nov; 40(23):3726-33. PubMed ID: 9371237
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.
Burgey CS; Robinson KA; Lyle TA; Nantermet PG; Selnick HG; Isaacs RC; Lewis SD; Lucas BJ; Krueger JA; Singh R; Miller-Stein C; White RB; Wong B; Lyle EA; Stranieri MT; Cook JJ; McMasters DR; Pellicore JM; Pal S; Wallace AA; Clayton FC; Bohn D; Welsh DC; Lynch JJ; Yan Y; Chen Z; Kuo L; Gardell SJ; Shafer JA; Vacca JP
Bioorg Med Chem Lett; 2003 Apr; 13(7):1353-7. PubMed ID: 12657281
[TBL] [Abstract][Full Text] [Related]
18. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates.
Sanderson PE; Lyle TA; Cutrona KJ; Dyer DL; Dorsey BD; McDonough CM; Naylor-Olsen AM; Chen IW; Chen Z; Cook JJ; Cooper CM; Gardell SJ; Hare TR; Krueger JA; Lewis SD; Lin JH; Lucas BJ; Lyle EA; Lynch JJ; Stranieri MT; Vastag K; Yan Y; Shafer JA; Vacca JP
J Med Chem; 1998 Nov; 41(23):4466-74. PubMed ID: 9804686
[TBL] [Abstract][Full Text] [Related]
19. Potent and selective proline derived dipeptidyl peptidase IV inhibitors.
Edmondson SD; Mastracchio A; Beconi M; Colwell LF; Habulihaz B; He H; Kumar S; Leiting B; Lyons KA; Mao A; Marsilio F; Patel RA; Wu JK; Zhu L; Thornberry NA; Weber AE; Parmee ER
Bioorg Med Chem Lett; 2004 Oct; 14(20):5151-5. PubMed ID: 15380217
[TBL] [Abstract][Full Text] [Related]
20. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.
Yamashita DS; Marquis RW; Xie R; Nidamarthy SD; Oh HJ; Jeong JU; Erhard KF; Ward KW; Roethke TJ; Smith BR; Cheng HY; Geng X; Lin F; Offen PH; Wang B; Nevins N; Head MS; Haltiwanger RC; Narducci Sarjeant AA; Liable-Sands LM; Zhao B; Smith WW; Janson CA; Gao E; Tomaszek T; McQueney M; James IE; Gress CJ; Zembryki DL; Lark MW; Veber DF
J Med Chem; 2006 Mar; 49(5):1597-612. PubMed ID: 16509577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
